In addition, in recent years, many non-targeted AR pathway therapies, such as PARP inhibitor or immune therapy [41–43], have been explored and discovered, aiming to explore new ways of prostate cancer treatment and combination drugs to enhance the therapeutic effect. This evidence concerns the gene AR and prostate cancer.